About Kymera Therapeutics
Inventing a new class of medicines using Targeted Protein Degradation
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Founded
- 2016
- Company type
- Public Company
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
Company locations
500 North Beacon Street, 4th Floor, Watertown, MA 02472, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 43,668
- People linked to this company
- 291
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.